Form 4: Director Pierre Boulud Receives STERIS Equity Grant

Director Pierre Boulud was granted 367 Career Restricted Stock Units by STERIS plc on June 2, 2026.

Summary

• Director Pierre Boulud acquired 367 Career Restricted Stock Units (CRSUs) on June 2, 2026.
• Each CRSU represents the right to receive one ordinary share of STERIS plc.
• The units are fully vested immediately upon grant.
• Settlement of the shares will occur six months after the director ceases board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Value of the equity grant is subject to future fluctuations in STERIS share price.

Future Outlook

The units will be settled in ordinary shares six months following the director's departure from the board.

Industry Context

StockSavvy.ai notes that this is a standard director compensation disclosure, reflecting typical corporate governance practices for equity-based retention of board members in the medical technology sector.

Comparison to Industry Standards

• The use of deferred equity grants for directors is a common practice among S&P 500 and large-cap healthcare companies to ensure long-term alignment.
• The structure of the grant is consistent with standard executive and director compensation packages for companies of similar market capitalization.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as the grant represents a standard component of director compensation.

Next Steps

• Settlement of shares to occur six months after the director's board service ends.

Key Dates

Keywords

STERIS, STE, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction